Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 241

Sort by

Sort Order Select

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 665.

https://doi.org/10.1182/blood-2025-665

Published: 2025

Journal Articles

Mechanistic role and prognostic value of CD20-positive microvesicles in rituximab-treated diffuse large B-cell lymphoma

Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim

Blood (2025) 146 (Supplement 1): 1756.

https://doi.org/10.1182/blood-2025-1756

Published: 2025

Journal Articles

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Mark Sorial, Kenechukwu Aniagboso, Emily Buttermore, Matthew Lei, Ellen Kendall, Kristiana Nasto, Min Jung Koh, Jessy Xinyi Han, Leora Boussi, Luis Malpica, Brady Beltran, Laura Korin, German Stemmelin, Carlos Chiattone, Denisse Castro, Fabiola Valvert, Jule Vasquez, Henry Quintero, Macarena Roa, Alfredo Quiroz, Marialejandra Torres Viera, Luis Mario Villela Martinez, Ana Oliver, Cesar Augusto Samanez Figari, Edith Julia, Vincent Camus, Catherine Thieblemont, Philippe Gaulard, Laurence de Leval, Franck Morschhauser, Emmanuel Bachy, Omar Elghawy, Stefan Barta, Jack Malespini, Kusha Chopra, Caroline MacVicar, Sean McCabe, Luke Peng, Shambhavi Singh, Makoto Iwasaki, Ijeoma Eche-Ugwu, Judith Gabler, Maria J Fernandez, Alexander Disciullo, Josie Ford, Alexandra Lenart, Emmanuel Nwodo, Jeffrey Barnes, Min Ji Koh, Eliana Miranda, Robert Stuver, Mwanasha Merrill, Eric Jacobsen, Martina Manni, Monica Civallero, Tetiana Skrypets, Athina Lymboussaki, Massimo Federico, Yu Ri Kim, Jin Seok Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Manju Sengar, Hasmukh Jain, Carrie Van Der Weyden, H. Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won-Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Maria Elena Cabrera, Govind Bhagat, Helen Ma, Ahmed Sawas, Dhruv Mistry, Khyati Kariya, Forum Bhanushali, Maya Krishnan, Erica Lee, Owen O'Conner, Enrica Marchi, Devavrat Shah, Changyu Shen, Salvia Jain

Blood (2025) 146 (Supplement 1): 889.

https://doi.org/10.1182/blood-2025-889

Published: 2025

Journal Articles

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Blood (2025) 146 (Supplement 1): 5352.

https://doi.org/10.1182/blood-2025-5352

Published: 2025

Journal Articles

Circulating extracellular Vesicle–Derived mirnas identify a high-risk subgroup in extranodal NK/T-cell lymphoma with caebv-like features

Kyung Ju Ryu, Bon Park, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim

Blood (2025) 146 (Supplement 1): 5311.

https://doi.org/10.1182/blood-2025-5311

Published: 2025

Journal Articles

Phased variant circulating tumor DNA (ctDNA) tracking provides limited additional power in predicting progressive disease compared with duplex variant tracking in patients with Relapsed/Refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) treated with odronextamab

Jon Arnason, Won Seog Kim, David Tucker, Sabarish Ayyappan, Wei-Yi Cheng, Weiwei Tao, Namita Gupta, Hesham Mohamed, Aafia Chaudhry, Jurriaan Brouwer-Visser

Blood (2025) 146 (Supplement 1): 5309.

https://doi.org/10.1182/blood-2025-5309

Published: 2025

Journal Articles

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Blood (2025) 146 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2025-1005

Published: 2025

Journal Articles

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Blood (2025) 146 (Supplement 1): 5519.

https://doi.org/10.1182/blood-2025-5519

Published: 2025

Journal Articles

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Blood (2025) 146 (Supplement 1): 5514.

https://doi.org/10.1182/blood-2025-5514

Published: 2025

Journal Articles

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

Yasmin Karimi, Chan Cheah, Julie Vose, Michael Roost Clausen, David Cunningham, Umar Farooq, Tatyana Feldman, Herve Ghesquieres, Wojciech Jurczak, Kim Linton, Tycel Phillips, Won Seog Kim, Pegah Jafarinasabian, Barbara D'Angelo Månsson, Milan Geybels, Christian Eskelund, Martin Hutchings, Catherine Thieblemont

Blood (2025) 146 (Supplement 1): 5513.

https://doi.org/10.1182/blood-2025-5513

Published: 2025

Journal Articles

Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy

Elizabeth Budde, Jason Westin, Huilai Zhang, Dai Maruyama, Eduardo M. Rego, Huangming Hong, Hideki Goto, Mark Fesler, Boone Goodgame, Zhiming Li, Adam Olszewski, Joan Ashby, Shen Yin, Wahib S. Ead, Martin Janousek, Song Pham, Connie L. Batlevi, Michael C. Wei, Won-Seog Kim

Blood (2025) 146 (Supplement 1): 5509.

https://doi.org/10.1182/blood-2025-5509

Published: 2025

Journal Articles

Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies

Won-Seog Kim, Dok Hyun Yoon, Youngil Koh, Seok Jin Kim, Sang Eun Yoon, Hyungwoo Cho, Jaewon Hyung, Ja Min Byun, Hyesung Jeon, Seungryel Han

Blood (2025) 146 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2025-1043

Published: 2025

Journal Articles

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Blood (2025) 146 (Supplement 1): 63.

https://doi.org/10.1182/blood-2025-63

Published: 2025

Journal Articles

SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma

Chan Cheah, Monique Menzies Wojtowicz, Catherine Thieblemont, Martin Hutchings, Prof. Dr. Max S Topp, Won-Seog Kim, Dai Maruyama, Azadeh Shohoudi, Robin Lesley, Wendy Chang, Marlene Zuraek, Mihail Obrocea, Jing-Zhou Hou

Blood (2025) 146 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2025-3747

Published: 2025

Journal Articles

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

Haifaa Abdulhaq, William Townsend, Matthew Ku, Gareth P. Gregory, Jeremy Abramson, Huiqiang Huang, Huilai Zhang, Dok Hyun Yoon, Won-Seog Kim, Herve Ghesquieres, Mark Hertzberg, Qing-Yuan Zhang, Murali Kesavan, Estefania Mulvihill, Martine Joanna Kallemeijn, Richard Ta, Voleak Choeurng, Linda Lundberg, Christopher Fox

Blood (2025) 146 (Supplement 1): 3743.

https://doi.org/10.1182/blood-2025-3743

Published: 2025

Journal Articles

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Blood (2025) 146 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2025-3646

Published: 2025

Journal Articles

Artificial intelligence (AI)–based membrane specific PD-L1 and immune subtypes as predictive biomarkers for danburstotug in relapsed or refractory extranodal NK/T cell lymphoma (R/R ENKTL): Insights from the Phase II trial (DISTINKT)

Won Seog Kim, Seok Jin Kim, Jae-Cheol Cho, Sang Eun Yoon, Youngil Koh, Deok-Hwan Yang, Dok Hyun Yoon, Junhun Cho, Sung Young Lee, Seongyeon Kang, Woochan Hwang, Hyukjung Kim, Heung Tae Kim

Blood (2025) 146 (Supplement 1): 5426.

https://doi.org/10.1182/blood-2025-5426

Published: 2025

Journal Articles

NB02 (Poseltinib) combined rituximab and lenalidomide in R/ R PCNSL (POTENTIAL-P): Initial results of safety lead-in cohort.

Deok-Hwan Yang, Sung Yong Oh, Youngwoo Jeon, Ga-Young Song, Seokjin Kim, Sang Eun Yoon, Tong-Yoon Kim, Ji Hyun Lee, Hye Ryeon Kim, Youngil Koh, Han Song, Myungsea Lee, Won Seog Kim

Blood (2025) 146 (Supplement 1): 5463.

https://doi.org/10.1182/blood-2025-5463

Published: 2025

Journal Articles

Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study

Blood (2025) 146 (Supplement 1): 2778.

https://doi.org/10.1182/blood-2025-2778

Published: 2025

Journal Articles

SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Blood (2025) 146 (Supplement 1): 3614.

https://doi.org/10.1182/blood-2025-3614

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Mechanistic role and prognostic value of CD20-positive microvesicles in rituximab-treated diffuse large B-cell lymphoma

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Circulating extracellular Vesicle–Derived mirnas identify a high-risk subgroup in extranodal NK/T-cell lymphoma with caebv-like features

Phased variant circulating tumor DNA (ctDNA) tracking provides limited additional power in predicting progressive disease compared with duplex variant tracking in patients with Relapsed/Refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) treated with odronextamab

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Artificial intelligence (AI)–based membrane specific PD-L1 and immune subtypes as predictive biomarkers for danburstotug in relapsed or refractory extranodal NK/T cell lymphoma (R/R ENKTL): Insights from the Phase II trial (DISTINKT)

NB02 (Poseltinib) combined rituximab and lenalidomide in R/ R PCNSL (POTENTIAL-P): Initial results of safety lead-in cohort.

Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study

SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only